Unigen will introduce its newest botanical ingredients for sleep/stress and immune health at this year’s SupplySide West Presentation Theater. MaizinolTM, a natural alternative to melatonin, and UP360 that maintains immune homeostasis are scheduled in the early afternoon of October 27th Supplier Presentation Theater and will be replayed online post-event on SSW 365 digital platform and www.unigen.net.
MaizinolTM is a patented ingredient derived from Zea mays corn leaf extract. The company’s Director of Pre-Clinical Development, Dr Mesfin Yimam, DVM, MS, will present the detailed clinical results on MaizinolTM, including the mechanism of action, preclinical efficacy, and safety profile. In the double-blind placebo-controlled clinical trial of healthy subjects on sleep quality and overall wellbeing, a statistically significant and dose-correlated increase in approximately 30% deep sleep time, improvement of sleep quality and reduction of salivary cortisol were observed.
According to Dr Qi Jia, Unigen CEO and CSO, “These collective health benefits give Maizinol™ a competitive edge in the market, to meet the needs of consumers who have experienced stress and lack of restful sleep under the rampage of the pandemic.” Another human clinical trial of Maizinol™ is in development with a larger cohort. He added that the supplement has a long history of safe human usage, once a day dosing, lower cost per serving, and its high compatibility in formulating with other ingredients denotes relative competitiveness to other similar ingredients in the market.
Dr Jia will present significant preclinical and clinical data on Unigen’s immune health ingredient, UP360. Its composition comprises polysaccharide and standardized polyphenol extracts from Aloe, Poria, and Rosemary formulated by evaluating the synergistic effects in protection from hyperoxia stressed macrophages. In an accelerated ageing model, UP360 increased key innate and acquired immunity while protecting immune organs.
Unigen also conducted a triple-blind placebo-controlled human clinical trial with influenza vaccine-immunized healthy subjects. UP360 resulted in a statistically significant increase of gamma delta T-cells, suggesting its benefits on enhanced immune surveillance in mucosal membranes.
